Renaissance Capital logo

Oncology biotech Monopar Therapeutics postpones $40 million IPO

October 2, 2019

Monopar Therapeutics, which is developing therapies for chemotherapy-induced mucositis and cancers, postponed its IPO on Wednesday, citing market conditions. It had filed to raise $40 million by offering 4.4 million shares at a price range of $8 to $10.

The Wilmette, IL-based company was founded in 2014 and had planned to list on the Nasdaq under the symbol MNPR. JonesTrading, Aegis Capital Corp., and Arcadia Securities were set to be the joint bookrunners on the deal.